Skip To Main Content
Xueying Jin on Muck Rack

Xueying Jin

As seen in: PLOS ONE, MDPI, Taylor & Francis Online, Royal Society of Chemistry, Optica, Journal of the American Medical Directors Association
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xueying

Contact Xueying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Plasma Image-Calibrated Double-Pulse Laser-Induced Breakdown Spectroscopy for High-Precision Quantification of Light Rare Earth Elements in Geological Matrix

|
By Xueying Jin, Ye Zhan, Zhongjie Xu, Jiaxuan Fang
| dx.doi.org
Open in Who Shared Issue with article?

Role of learning experiences of care knowledge and skills on caregiver burden and self-esteem among informal caregivers: an observational cross-sectional study

|
By Taiji Noguchi, Xueying Jin, Takeshi Nakagawa, Ayane Komatsu
| Taylor & Francis Online
Abstract Objectives Acquiring caregiving knowledge and skills may reduce informal caregivers’ burden and enhance positive feelings, yet evidence on the impact of the learning across caregiving domains is limited. We examined the association between learning experiences in caregiving knowledge/skills and caregivers’ negative and positive outcomes.
Open in Who Shared Issue with article?

The cost-effectiveness of toripalimab combined with chemotherapy versus chemotherapy alone in the first-line treatment of extensive-stage small cell lung cancer in China: the perspective of the medical and health system based on the EXTENTORCH study

|
By Xueying Jin, Shengkai Zhao, Zekai Zhao, Jianguo Zhao
| Taylor & Francis Online
ABSTRACT Objective To evaluate the cost-effectiveness of toripalimab combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer. Methods A partitioned survival model was employed with data sourced from the EXTENTORCH clinical trial and related literature. The simulation period was set to 10 years, with a cycle of 3 weeks, and all cost and utility indicators were adjusted using a 5% annual discount rate.
Open in Who Shared Issue with article?
See all 11 licensed articles (12 Total)